A Phase II, Randomized, Double-blind, Active-controlled Study to Assess the Safety and Efficacy of NBI-56418 in Subjects With Endometriosis

This study is designed to assess the effects of elagolix versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC; also known as depo-provera) on bone mineral density (BMD) during treatment for 24 weeks with a subsequent 24-week post-treatment period.

本研究旨在评估艾拉戈克（elagolix）与醋酸甲羟孕酮皮下缓释制剂（subcutaneous depot medroxyprogesterone acetate, DMPA-SC，又称普维拉注射液（depo-provera））在24周治疗阶段及后续24周治疗后随访期内对骨密度（BMD）的影响。